Patents by Inventor Xiaokui Wang
Xiaokui Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240068721Abstract: A system for refrigerant leakage detection includes one or more sensors configured to detect one or more parameters of a building system including a refrigerant. The system further includes one or more storage devices storing instructions thereon that, when executed by one or more processors, cause the one or more processors to receive sensor data from the one or more sensors; apply the sensor data to a long short-term memory (LSTM) model to generate predicted sensor data corresponding to the one or more sensors; receive subsequent sensor data from the one or more sensors; compare the predicted sensor data to the subsequent sensor data; determine that the building system has a refrigerant leakage based on the comparison of the predicted sensor data to the subsequent sensor data; and, responsive to determining that the building system has the refrigerant leakage, take an action to address the refrigerant leakage.Type: ApplicationFiled: August 30, 2023Publication date: February 29, 2024Inventors: Zhanhui Feng, Xiaokui Ma, Li Wang, Baojun Chang
-
Patent number: 11447463Abstract: The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.Type: GrantFiled: April 9, 2019Date of Patent: September 20, 2022Assignee: Institute of Pharmacology and Toxicology Academy of Millitary Medical Sciences P.L.A. ChinaInventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang
-
Publication number: 20210261505Abstract: Provided are a linker represented by Formula I or I?, an antibody-drug conjugate containing the same, and use of thereof, a pharmaceutical composition comprising the antibody-drug conjugate, and use of the antibody-drug conjugate for treating and/or preventing a disease.Type: ApplicationFiled: August 15, 2019Publication date: August 26, 2021Inventors: Xinbo ZHOU, Yanming WANG, Shiyong FAN, Song LI, Wu ZHONG, Junhai XIAO, Zhibing ZHENG, Xingzhou LI, Dian XIAO, Yunde XIE, Xiaokui WANG, Ruiyuan CAO
-
Publication number: 20210205464Abstract: The present application relates to a linker containing arylnitro, an antibody-drug conjugate the linker and use of the linker, as well as a pharmaceutical composition comprising the antibody-drug conjugate and use of the antibody-drug conjugate for treatment and/or prevention of a disease.Type: ApplicationFiled: August 28, 2019Publication date: July 8, 2021Inventors: Xinbo ZHOU, Yanming WANG, Song LI, Wu ZHONG, Shiyong FAN, Dian XIAO, Junhai XIAO, Zhibing ZHENG, Xingzhou LI, Yunde XIE, Ruiyuan CAO, Xiaokui WANG
-
Patent number: 10759822Abstract: Disclosed in the present invention is a compound of Formula (I), a geometric or optical isomer, a pharmaceutically acceptable salt, a solvate or a polymorph thereof. Also disclosed in the present invention is a composition comprising the compound of Formula (I), the geometric or optical isomer, the pharmaceutically acceptable salt, the solvate or the polymorph thereof. Also disclosed in the present invention is a use of the compound of Formula (I), the geometric or optical isomer, the pharmaceutically acceptable salt, the solvate or the polymorph thereof in the treatment of a disease or disorder such as a hypoglutamatergic condition, a neurodegenerative disease or respiratory depression, particularly in the treatment of a disease or disorder associated with AMPA receptor.Type: GrantFiled: April 11, 2017Date of Patent: September 1, 2020Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Xinbo Zhou, Dian Xiao, Wu Zhong, Junhai Xiao, Zhibing Zheng, Xingzhou Li, Yunde Xie, Xiaokui Wang
-
Patent number: 10647690Abstract: The present invention relates to a 2,3-epoxy succinyl derivative, a preparation method and a use thereof, in particular, the present invention relates to a compound represented by Formula (1), a racemate or an optical isomer thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof. The compound according to the present invention has good inhibitory activity and/or selectivity against cathepsin, especially Cathepsin B, can be used in the treatment of multiple diseases associated with cathepsin, for example, osteoporosis, rheumatoid arthritis and osteoarthritis that are associated with Cathepsin K, Ebola virus infection, a degenerative disease and an autoimmune disease that are associated with Cathepsin L, S, especially Cathepsin B-related tumor diseases, such as gastric cancer, cervical cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, colon cancer, neuroglioma, and melanoma.Type: GrantFiled: March 2, 2017Date of Patent: May 12, 2020Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Junhai Xiao, Xiaoye Zhang, Hongliang Wang, Wu Zhong, Zhibing Zheng, Yunde Xie, Xingzhou Li, Xinbo Zhou, Xiaokui Wang
-
Patent number: 10611742Abstract: The present invention relates to a compound represented by Formula I, a racemate or optical isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof, a pharmaceutical composition comprising the compound, and a use thereof in the manufacture of a medicament for preventing and/or treating a disease or disorder associated with a viral infection.Type: GrantFiled: November 24, 2016Date of Patent: April 7, 2020Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Junhai Xiao, Libao Xu, Ruiyuan Cao, Fangyuan Cao, Hongliang Wang, Wu Zhong, Zhibing Zheng, Yunde Xie, Xingzhou Li, Xinbo Zhou, Xiaokui Wang
-
Publication number: 20190233390Abstract: The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.Type: ApplicationFiled: April 9, 2019Publication date: August 1, 2019Applicant: Institute of Pharmacology and Toxicology Academy of Millitary Medical Sciences P.L.A. ChinaInventors: Wu ZHONG, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang
-
Patent number: 10335417Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to a thiazideamide derivative compound or a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt or solvate thereof, a method for preparing the compound or a pharmaceutically acceptable salt or solvate thereof, and a use of the compound or a pharmaceutically acceptable salt or solvate thereof. For example, the compound or a pharmaceutically acceptable salt or solvate thereof according to the invention can be used to prevent and/or treat a neurodegenerative disease or a neuropathic disease caused by a physical trauma or a related disease.Type: GrantFiled: June 28, 2016Date of Patent: July 2, 2019Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Junhai Xiao, Boqun Lyu, Hongqiang Wang, Wu Zhong, Lili Wang, Zhibing Zheng, Yunde Xie, Xinbo Zhou, Xingzhou Li, Xiaokui Wang
-
Patent number: 10301279Abstract: The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.Type: GrantFiled: October 26, 2017Date of Patent: May 28, 2019Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang
-
Publication number: 20190077821Abstract: Disclosed in the present invention is a compound of Formula (I), a geometric or optical isomer, a pharmaceutically acceptable salt, a solvate or a polymorph thereof. Also disclosed in the present invention is a composition comprising the compound of Formula (I), the geometric or optical isomer, the pharmaceutically acceptable salt, the solvate or the polymorph thereof. Also disclosed in the present invention is a use of the compound of Formula (I), the geometric or optical isomer, the pharmaceutically acceptable salt, the solvate or the polymorph thereof in the treatment of a disease or disorder such as a hypoglutamatergic condition, a neurodegenerative disease or respiratory depression, particularly in the treatment of a disease or disorder associated with AMPA receptor.Type: ApplicationFiled: April 11, 2017Publication date: March 14, 2019Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Xinbo ZHOU, Dian XIAO, Wu ZHONG, Junhai XIAO, Zhibing ZHENG, Xingzhou LI, Yunde XIE, Xiaokui WANG
-
Publication number: 20190062290Abstract: The present invention relates to a 2,3-epoxy succinyl derivative, a preparation method and a use thereof, in particular, the present invention relates to a compound represented by Formula (1), a racemate or an optical isomer thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof. The compound according to the present invention has good inhibitory activity and/or selectivity against cathepsin, especially Cathepsin B, can be used in the treatment of multiple diseases associated with cathepsin, for example, osteoporosis, rheumatoid arthritis and osteoarthritis that are associated with Cathepsin K, Ebola virus infection, a degenerative disease and an autoimmune disease that are associated with Cathepsin L, S, especially Cathepsin B-related tumor diseases, such as gastric cancer, cervical cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, colon cancer, neuroglioma, and melanoma.Type: ApplicationFiled: March 2, 2017Publication date: February 28, 2019Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Junhai XIAO, Xiaoye ZHANG, Hongliang WANG, Wu ZHONG, Zhibing ZHENG, Yunde XIE, Xingzhou LI, Xinbo ZHOU, Xiaokui WANG
-
Patent number: 10196411Abstract: The invention relates to tizoxanide phosphate or alkane sulfonate compounds represented by Formula I, and pharmaceutically acceptable salts thereof, isomers thereof, hydrates thereof or solvates thereof, and pharmaceutical applications of the compounds.Type: GrantFiled: December 11, 2015Date of Patent: February 5, 2019Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Xingzhou Li, Wu Zhong, Zhibing Zheng, Junhai Xiao, Xinbo Zhou, Yunde Xie, Xiaokui Wang, Lili Wang, Wei Chen, Fei Xie
-
Patent number: 10196346Abstract: The present invention pertains to the field of pharmaceutical chemicals, and relates to a substituted acethydrazide derivative, preparation method and use thereof; preferably, relates to a compound of Formula I or a pharmaceutically acceptable salt thereof. The compound of the present invention or a pharmaceutically acceptable salt thereof can effectively inhibit proline hydroxylase, stabilize HIF-?, particularly HIF-1?, and has potency in the manufacture of a medicament for treatment and/or prophylaxis and/or adjuvant therapy of anemia, acute ischemic reperfusion injury.Type: GrantFiled: November 20, 2017Date of Patent: February 5, 2019Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Junhai Xiao, Lili Wang, Long Long, Wei Li, Haoming Luo, Feifei Li, Wu Zhong, Zhibing Zheng, Yunde Xie, Xingzhou Li, Xinbo Zhou, Xiaokui Wang, Ruiyuan Cao
-
Publication number: 20180370928Abstract: The present invention relates to a compound represented by Formula I, a racemate or optical isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof, a pharmaceutical composition comprising the compound, and a use thereof in the manufacture of a medicament for preventing and/or treating a disease or disorder associated with a viral infection.Type: ApplicationFiled: November 24, 2016Publication date: December 27, 2018Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Junhai XIAO, Libao XU, Ruiyuan CAO, Fangyuan CAO, Hongliang WANG, Wu ZHONG, Zhibing ZHENG, Yunde XIE, Xingzhou LI, Xinbo ZHOU, Xiaokui WANG
-
Patent number: 10131643Abstract: The invention relates to a tizoxanide carbamate compound of Formula I and a pharmaceutically acceptable salt, a hydrate or a solvate thereof, and their pharmaceutical use.Type: GrantFiled: July 4, 2014Date of Patent: November 20, 2018Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Xingzhou Li, Wu Zhong, Zhibing Zheng, Junhai Xiao, Xinbo Zhou, Yunde Xie, Xiaokui Wang, Lili Wang, Wei Chen, Fei Xie
-
Patent number: 10071994Abstract: The invention relates to a homoserine lactone derivative of Formula I, preparation method and use thereof.Type: GrantFiled: May 25, 2015Date of Patent: September 11, 2018Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Junhai Xiao, Qi Sun, Wu Zhong, Lili Wang, Zhibing Zheng, Yunde Xie, Xingzhou Li, Xinbo Zhou, Xiaokui Wang, Ruiyuan Cao
-
Patent number: 10023565Abstract: The present invention relates to a compound of formula (I), a stereomeride, pharmaceutically acceptable salt, a solvate or an N-oxide thereof, a medicine composition comprising the compound, a method for preparing the compound, and a usage of the compound in treating diseases related to Hsp70. The diseases are preferably selected from tumors, neurodegenerative diseases, and allogeneic transplantation rejection and infection.Type: GrantFiled: December 19, 2014Date of Patent: July 17, 2018Assignee: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINAInventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang, Lili Wang
-
Publication number: 20180185376Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to a thiazideamide derivative compound or a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt or solvate thereof, a method for preparing the compound or a pharmaceutically acceptable salt or solvate thereof, and a use of the compound or a pharmaceutically acceptable salt or solvate thereof. For example, the compound or a pharmaceutically acceptable salt or solvate thereof according to the invention can be used to prevent and/or treat a neurodegenerative disease or a neuropathic disease caused by a physical trauma or a related disease.Type: ApplicationFiled: June 28, 2016Publication date: July 5, 2018Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Junhai XIAO, Boqun LYU, Hongqiang WANG, Wu ZHONG, Lili WANG, Zhibing ZHENG, Yunde XIE, Xinbo ZHOU, Xingzhou LI, Xiaokui WANG
-
Publication number: 20180179193Abstract: The invention relates to a homoserine lactone derivative of Formula I, preparation method and use thereof. The compound has an effect of regulatory of bacterial quorum sensing, and is useful for preventing and/or treating a disease caused by infection of a bacterium.Type: ApplicationFiled: May 25, 2015Publication date: June 28, 2018Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Junhai XIAO, Qi SUN, Wu ZHONG, Lili WANG, Zhibing ZHENG, Yunde XIE, Xingzhou Li, Xinbo ZHOU, Xiaokui WANG, Ruiyuan CAO